Celsius Therapeutics: Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale. The Company’s SCOPE (Single Cell Observations for Precision Effect) platform provides a new way to understand the cells that drive disease progression, leading to new insights into targets and patient subsets, resulting in more precise drug discovery and development. The Company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease that will enter the clinic in H1-23, and the company has multiple ongoing drug discovery programs in oncology. Celsius is based in Cambridge, MA.